A very rare case of cutaneous toxicity of API protocol

N Filali*, S-H Touimi‡; G Akimana‡; H Elkacemi§; S Elmouhtadi‡; T Kebdani‡; N Benjaafar‡; H Errhani‡

1Department of Oncology, National Institute of Oncology, Rabat, Morocco
2Department of Radiotherapy, National Institute of Oncology, Rabat, Morocco

*Corresponding Author(s): N Filali
Department of Oncology, National Institute of Oncology, Rabat, Morocco
Tel: 00212-660-77-1429;
Email: nadiafilali08@gmail.com

Received: Mar 12, 2020
Accepted: Apr 20, 2020
Journal: Journal of Clinical Images
Publisher: MedDocs Publishers LLC
Online edition: http://meddocsonline.org/
Copyright: © Filali N (2020). This Article is distributed under the terms of Creative Commons Attribution 4.0 International License

Clinical image description

It’s a 36 years old female patient treated 7 years ago for an osteochondroma of the upper third of the left humerus by surgery alone. She was under follow-up since then. Five months ago, she presented a mass in the same previous location. CT scan showed a locally advanced tumor of the left humerus.

A biopsy of the mass showed a low-grade osteosarcoma with high-grade osteosarcoma differentiation foci.

The remainder of the staging didn’t reveal any metastases.

The patient received 1 course of chemotherapy neoadjuvant to surgery with Adriamycin – Cisplatin – Ifosfamid (API). She presented 3 days later right laterocervical skin lesions which extend in one week to the homolateral upper hemithorax, likely related to rare cutaneous toxicity of the protocol.

Figure 1: A 36 years old patient with a rare cutaneous toxicity of API protocol